CEMEC CTO (CPAM - Centro de Pesquisas da Amazônia)

Belém 66073-005

1 studies enrolling now · 1 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer, PIK3CA Mutation

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now